Apollo Hospitals Enterprise Limited has secured approval from the National Company Law Tribunal (NCLT), Chennai bench, for its proposed composite scheme of arrangement. The restructuring involves four entities and will create a new focused company, Apollo HealthTech Limited (AHTL), by consolidating Apollo Healthco and Keimed. This move separates and strengthens the digital health and pharmacy distribution businesses while unlocking shareholder value.
Glimpse:
The NCLT order, dated March 26, 2026, directs Apollo to convene meetings of equity shareholders, secured creditors, and unsecured creditors to seek their approval. Once completed, the healthtech vertical (combining Apollo 24|7 digital platform, pharmacy retail, and wholesale operations) will be demerged and listed separately on the stock exchange. The new entity targets revenue of ₹25,000 crore by FY27. The scheme remains subject to final NCLT sanction and other regulatory approvals.
Apollo Hospitals Enterprise Limited has taken a significant step in its corporate restructuring journey after receiving approval from the National Company Law Tribunal (NCLT), Chennai bench. The tribunal has cleared the company’s application for a composite scheme of arrangement involving Apollo Hospitals Enterprise, Apollo Healthco, Keimed, and Apollo Healthtech.
The proposed restructuring aims to create a distinct, technology focused entity by merging Apollo Healthco and Keimed into the new Apollo HealthTech Limited (AHTL). This new company will consolidate Apollo’s digital health platform (Apollo 24|7), extensive pharmacy retail and distribution network, and wholesale pharmaceutical operations under one umbrella. The move is expected to improve operational efficiency, allow sharper strategic focus on each business vertical, and unlock greater value for shareholders.
The NCLT order dated March 26, 2026, has directed Apollo to hold meetings of equity shareholders, secured creditors, and unsecured creditors to consider and approve the scheme. Following these approvals and other necessary statutory and regulatory clearances, the healthtech business will be demerged and listed as a separate entity on the stock exchanges. Apollo Healthtech has set an ambitious target of achieving ₹25,000 crore in revenue by fiscal year 2027.
This restructuring reflects Apollo’s strategy to capitalise on the fast growing digital health and pharmacy sectors while maintaining its core hospital business as a separate, focused vertical. In a parallel development, the company has also received board approval to set up a new multi-speciality hospital in Dwarka, New Delhi, to be implemented in phases.
“The proposed restructuring will create a new entity, Apollo HealthTech Limited, which will consolidate two other entities, Apollo Healthco and Keimed, into AHTL. This consolidation brings together the digital platform, pharmacy distribution, and wholesale pharmaceutical operations.”
By
HB Team
